---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061548"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:32:48.919579+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q3 net loss $20.1M ($0.45/diluted); cash $159.9M; hematuria resolution data at ASN

## Summary
- Net loss of $20.1M ($0.45 per diluted share) vs $24.7M ($0.91) in Q3 2022.
- Cash, cash equivalents and securities $159.9M; cash burn $67.0M in nine months.
- Phase 2b OLE eGFR and proteinuria data expected Q1 2024; pivotal Phase 3 ORIGIN 3 enrolling.
- At ASN Kidney Week: 80% of atacicept patients achieved hematuria resolution vs 5% placebo.
- Enrollment of Phase 3 ORIGIN 3 estimated to complete H2 2024; topline data H1 2025.

## SEC filing metadata
- accession: 0000950170-23-061548
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017023061548/0000950170-23-061548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017023061548/vera-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061548
- JSON: https://secwatch.observer/filing/0000950170-23-061548.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061548.txt

## Key facts
- Earnings Releases
  Vera Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $20.1 million, EPS $0.45.
  - Period: the third quarter ended September 30, 2023
  - Net income: $20.1 million
  - EPS: $0.45
  - Result: reported results
  source text: For the quarter ended September 30, 2023, the company reported a net loss of $20.1 million, or a net loss per diluted share of $0.45
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017023061548/0000950170-23-061548-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.